

The following are representative references picked out.

■ PBMC/ CELLBANKER 1

Mechanisms of action and resistance in histone methylation-targeted therapy.

Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, Makiyama J, Suzuki K, Seki M, Abe K, Imamura K, Watanabe E, Tsuchiya K, Yasumatsu I, Takayama G, Hizukuri Y, Ito K, Taira Y, Nannya Y, Tojo A, Watanabe T, Tsutsumi S, Suzuki Y, Uchimaru K. Nature. 2024 Mar;627(8002):221-228.

<https://www.nature.com/articles/s41586-024-07103-x>

■ PBMC/ CELLBANKER 1

A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients.

Søndergaard JN, Tulyeu J, Edahiro R, Shirai Y, Yamaguchi Y, Murakami T, Morita T, Kato Y, Hirata H, Takeda Y, Okuzaki D, Sakaguchi S, Kumanogoh A, Okada Y, Wing JB. Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2217902120.

<https://www.pnas.org/doi/abs/10.1073/pnas.2217902120>

■ PBMC/ CELLBANKER 1Plus

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain.

Takano T, Sato T, Kotaki R, Moriyama S, Fukushi S, Shinoda M, Kabasawa K, Shimada N, Kousaka M, Adachi Y, Onodera T, Terahara K, Isogawa M, Matsumura T, Shinkai M, Takahashi Y. Nat Commun. 2023 Mar 15;14(1):1451.

<https://www.nature.com/articles/s41467-023-37128-1>

■ PBMC/ CELLBANKER 2

Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19.

Lee CM, Choe PG, Kang CK, Lee E, Song KH, Bang JH, Kim ES, Kim HB, Kim NJ, Kim HR, Kim Y, Lee CH, Shin HM, Park SW, Park WB, Oh MD. Front Immunol. 2023 Mar 22;14:1106664.

<https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1106664/full>

■ PBMC/ CELLBANKER 1

Single-cell RNA sequencing identifies distinct transcriptomic signatures between PMA/ionomycin- and alphaCD3/alphaCD28-activated primary human T cells.

Lee JH, Lee BH, Jeong S, Joh CS, Nam HJ, Choi HS, Sserwadda H, Oh JW, Park CG, Jin SP, Kim HJ. Genomics Inform. 2023 Jun;21(2):e18.

<https://genominfo.org/journal/view.php?doi=10.5808/gi.23009>

The following are representative references picked out.

■ PBMC/ CELLBANKER 2

Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection.

Kang CK, Shin HM, Choe PG, Park J, Hong J, Seo JS, Lee YH, Chang E, Kim NJ, Kim M, Kim YW, Kim HR, Lee CH, Seo JY, Park WB, Oh MD.

BMC Med(2022) May 4;20(1):181.

<https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-022-02383-4>

■ PBMC/ STEM-CELLBANKER

A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population.

Yoshida S, Kato T, Sato Y, Umekage M, Ichisaka T, Tsukahara M, Takasu N, Yamanaka S.

Med. 2023 Jan 13;4(1):51-66.e10.

<https://www.sciencedirect.com/science/article/pii/S2666634022004500>

■ PBMC/ CELLBANKER 2

Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients.

Mao JX, Guo WY, Guo M, Liu C, Teng F, Ding GS.

Hepatol Int. 2020 May;14(3):347-361.

<https://link.springer.com/article/10.1007/s12072-020-10022-4>

■ PBMC/ STEM-CELLBANKER

Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521.

Skorik C, Mullin NK, Shi M, Zhang Y, Hunter P, Tang Y, Hilton B, Schlaeger TM.

Curr Protoc Stem Cell Biol. 2020 Mar;52(1):e103.

<https://currentprotocols.onlinelibrary.wiley.com/doi/10.1002/cpsc.103>

■ PBMC/ STEM-CELLBANKER

Generation of an ALS human iPSC line KEIOi001-A from peripheral blood of a Charcot disease-affected patient carrying TARDBP p.N345K heterozygous SNP mutation.

Leventoux N, Morimoto S, Hara K, Nakamura S, Ozawa F, Mitsuzawa S, Akiyama T, Nishiyama A, Suzuki N, Warita H, Aoki M, Okano H.

Stem Cell Res. 2020 Jun 28;47:101896.

<https://www.sciencedirect.com/science/article/pii/S1873506120301975>